Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 10/20 | 0.46 |
| ▸ | RAB9A | P51151 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933064 | 0.88 | RAB9A (0.55) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23933083 | 0.82 | S1PR3 (0.54) | MAPTRAB9AFBP1S1PR1S1PR3 | |
| SCHEMBL23932941 | 0.82 | HCRTR1 (0.42) | S1PR1S1PR3 | |
| SCHEMBL23932822 | 0.81 | FBP1 (0.47) | KDM4EFBP1 | |
| SCHEMBL15450923 | 0.80 | PIK3CA (0.51) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2134640 | 0.79 | MAPT (0.54) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2544240 | 0.78 | MAPT (0.48) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11258897 | 0.78 | AGPAT2 (0.58) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL880339 | 0.78 | NPC1 (0.53) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22468052 | 0.76 | NPC1 (0.50) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-13 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3728211-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2020-10-28 | — | — | EP | disclosed |
| CN-111836803-A | Compounds and their use in the treatment of cancer | 国家科学研究中心 | 2020-10-27 | — | — | CN | disclosed |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | MAPT 2129/4885KDM4E 2218/4885NPC1 3021/4885 |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | BCR, G6PD, BRAF | MAPT 4792/4885KDM4E 2241/4885NPC1 4467/4885 |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | BCR, G6PD, BRAF | MAPT 4792/4885KDM4E 2241/4885NPC1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.